I have enough context from the report and my medical knowledge to provide a clear, thorough summary. Here is a plain-language explanation of the PET-CT report for Dev Dutt Maithani, 76-year-old male, dated 15 May 2026, from Kailash Omega Cancer Centre, Dehradun.
PET-CT Report Summary
What is this scan?
A Whole Body ¹⁸F-FDG PET-CT is a nuclear medicine scan that combines a metabolic scan (PET) with a CT scan. Cancer cells are "FDG avid" — they absorb more glucose, which shows up as bright spots. The SUVmax number indicates how metabolically active (how "hot") a lesion is — higher values generally indicate more aggressive or malignant tissue.
Key Findings
🫁 LUNGS (Most Important Finding)
- A large, spiculated (spiky-edged) soft tissue mass is present in the upper lobe of the right lung, measuring approximately 4.0 × 5.9 × 3.5 cm — roughly the size of a golf ball.
- It has a very high SUVmax of 12.0, which is strongly suggestive of a primary malignant (cancerous) tumour.
- The mass is pressing against the right oblique fissure and encasing the subsegmental bronchi (airways), causing consolidation (partial collapse/fluid) nearby.
- It extends toward the parahilar region (near the lung root) and is abutting the right main bronchus and right paratracheal lymph nodes.
🔴 LYMPH NODES (Likely Spread to Nearby Nodes)
- A right lower paratracheal lymph node (in the chest, near the windpipe) is enlarged at ~3.8 × 2.8 cm with SUVmax 14.5 — this is highly suspicious for cancer spread (metastasis).
- Several other mediastinal lymph nodes (paraaortic, AP window, subcarinal, right hilar) show mild FDG activity (SUVmax ~5.1) — the radiologist considers these possibly inflammatory, but metastasis cannot be excluded.
🧠 BRAIN
- No brain metastases seen on PET-CT. However, the report notes that brain MRI should be done if clinically suspected, as PET-CT can miss small brain lesions.
- Age-related brain atrophy (normal for 76 years).
🔄 REST OF THE BODY — No Spread Detected
- Liver: Mild fatty infiltration (common finding); no cancer deposits.
- Spleen, Pancreas, Adrenals: All normal.
- Kidneys: Simple benign cysts (non-cancerous); otherwise normal.
- Abdomen/Pelvis lymph nodes: One small portocaval node seen, likely inflammatory.
- Bowel, Stomach: Unremarkable.
- Bones: Degenerative spine changes, dense sclerosis in right femur neck (likely benign). No bone metastases.
- Prostate: Post-TURP changes (prior surgery). Otherwise unremarkable.
Other Incidental Findings
- Atherosclerotic calcification in the aorta (expected at this age).
- Fatty degeneration of right masseter muscle (jaw muscle).
- Dental implants causing image artefact.
- Blood glucose at time of scan: 124 mg/dL (mildly elevated — important to note as it can slightly reduce scan sensitivity).
Radiologist's Opinion (Dr. Sudip Dey)
The scan is suggestive of:
- Primary lung cancer in the upper right lobe — likely a primary malignant tumour (the word "mitotic" in the report is used in the Indian radiology context to mean "neoplastic/cancerous")
- Right lower paratracheal lymph node metastasis — cancer has likely spread to this nearby lymph node
- Other mediastinal lymph nodes — likely inflammatory, but metastasis cannot be ruled out
- No distant (far) metastases detected elsewhere in the body
The radiologist strongly recommends histopathological (tissue biopsy) correlation to confirm diagnosis.
What This Means — Next Steps
This report is very concerning for lung cancer (likely Non-Small Cell Lung Cancer, NSCLC) with possible involvement of regional lymph nodes. Based on the imaging, the disease appears to be locally advanced (Stage IIIA/IIIB), but a definitive stage can only be assigned after biopsy.
Urgently Recommended Actions:
- Tissue Biopsy (most important) — A CT-guided biopsy, bronchoscopy, or EBUS (endobronchial ultrasound-guided biopsy) is needed to confirm whether this is cancer and what type (adenocarcinoma, squamous cell, etc.). This determines all treatment decisions.
- Brain MRI — To rule out small brain metastases not visible on PET-CT.
- Molecular/Genomic Testing — If cancer is confirmed, tissue should be tested for EGFR, ALK, PD-L1, and other markers, as these guide targeted therapy and immunotherapy options.
- Pulmonary Function Tests (PFTs) — To assess lung reserve, especially if surgery is being considered.
- Multidisciplinary Team (MDT) Consultation — Oncologist, pulmonologist, thoracic surgeon, and radiation oncologist should review the case together.
⚠️ Important Note
This is a serious report that requires urgent specialist attention. The patient should be seen promptly by a medical oncologist or thoracic oncologist. Do not delay — early evaluation and treatment planning significantly affects outcomes in lung cancer. The referring physician, Dr. Vivek Kumar Verma, should be contacted immediately to arrange the next steps.
This summary is for informational purposes only and does not replace the advice of the treating medical team who can examine the patient directly.